Formulation: A solution in ethanol
Formal Name: (S)-4-(6-((1S,3R)-3-(1H-pyrazol-1-yl)cyclobutoxy)pyrimidin-4-yl)-2-phenylmorpholine
Purity: ā„98%
Formula Markup: C21H23N5O2
Formula Weight: 377,4
Shelf life (days): 365
Notes: ELOVL1-22 is an inhibitor of ELOVL fatty acid elongase 1 (ELOVL1).{62719} It reduces lysohexacosanoylphosphatidylcholine (LPC(C26:0)) synthesis in HEK293 cells (IC50 = 400 pM), a marker of ELOVL1 inhibition, and is selective for ELOVL1 over ELOVL4, -6, and -7 (IC50s = >50 ĀµM for all), as well as a panel of 34 receptors at 10 ĀµM. ELOVL1-22 (1-32 mg/kg) reduces blood and CNS levels of LPC(C26:0) in an Abcd1-/- mouse model of adrenoleukodystrophy (ALD), a neurodegenerative disease characterized by rapid inflammatory demyelination of the CNS.